Dr Chen-Yu Huang

Postdoctoral Research Fellow
Sydney Medical School

Telephone +61 9036 5013

Map

Biographical details

The efficacy of radiotherapy is decreased by tumour motion. If left uncorrected, this motion causes the radiation beam to miss the tumour, compromising cancer control and increasing toxicity. Dr. Chen-Yu Huang is developing the world’s first radiotherapy system capable of measuring and adapting to tumour motion during treatment. This innovative system will lead to high precision cancer radiotherapy, increasing survival and quality of life for the 44,000 Australian cancer radiotherapy patients every year.

Research interests

Real-time image guidance; kilovoltage image; tumor motion; motion managment; prostate tumor; lung tumor

Radiobiology; radioimmunotherapy ; Monte Carlo; endothelial cell

Teaching and supervision

Geant4 Monte Carlo simulation

Current projects

-- Quantify prostate and lung tumor rotation during radiation therapy

-- Design and develop new procedures to commission a 6 degree-of-freedom motion platform – Hexamotion

-- Perform quality assurance for the Kilovoltage Intrafraction Monitoring clinical trial for prostate cancer

-- Develop the real-time 6 degree-of-freedom tumor motion measurement system

-- Develop the real-time 6 degree-of-freedom tumor motionadaptationsystem

Selected grants

2014

  • Learning Image Context for Tumor Motion Adaptation to Improve Cancer Radiotherapy Treatment Outcomes; Huang C, Keall P, Fahrig R, Wang X; DVC International/IPDF Grant.

Selected publications

Download citations: PDF RTF Endnote

Journals

  • Ng, J., Booth, J., O'Brien, R., Colvill, E., Huang, C., Poulsen, P., Keall, P. (2014). Quality assurance for the clinical implementation of kilovoltage intrafraction monitoring for prostate cancer VMAT. Medical Physics, 41(11), 1-9. [More Information]
  • Allen, B., Huang, C., Clarke, R. (2014). Targeted alpha anticancer therapies: update and future prospects. Biologics: Targets and Therapy, 8, 255-267. [More Information]
  • Huang, C., Guatelli, S., Oborn, B., Allen, B. (2012). Microdosimetry for Targeted Alpha Therapy of Cancer. Computational and Mathematical Methods in Medicine, 2012, 1-6. [More Information]
  • Huang, C., Oborn, B., Guatelli, S., Allen, B. (2012). Monte Carlo calculation of the maximum therapeutic gain of tumor antivascular alpha therapy. Medical Physics, 39(3), 1282-1288. [More Information]
  • Huang, C., Pourgholami, M., Allen, B. (2012). Optimizing radioimmunoconjugate delivery in the treatment of solid tumor. Cancer Treatment Reviews, 38(7), 854-860. [More Information]
  • Huang, C., Guatelli, S., Oborn, B., Allen, B. (2011). Background Dose for Systemic Targeted Alpha Therapy. Journal of Nuclear Science and Technology, 2, 187-190.

2014

  • Ng, J., Booth, J., O'Brien, R., Colvill, E., Huang, C., Poulsen, P., Keall, P. (2014). Quality assurance for the clinical implementation of kilovoltage intrafraction monitoring for prostate cancer VMAT. Medical Physics, 41(11), 1-9. [More Information]
  • Allen, B., Huang, C., Clarke, R. (2014). Targeted alpha anticancer therapies: update and future prospects. Biologics: Targets and Therapy, 8, 255-267. [More Information]

2012

  • Huang, C., Guatelli, S., Oborn, B., Allen, B. (2012). Microdosimetry for Targeted Alpha Therapy of Cancer. Computational and Mathematical Methods in Medicine, 2012, 1-6. [More Information]
  • Huang, C., Oborn, B., Guatelli, S., Allen, B. (2012). Monte Carlo calculation of the maximum therapeutic gain of tumor antivascular alpha therapy. Medical Physics, 39(3), 1282-1288. [More Information]
  • Huang, C., Pourgholami, M., Allen, B. (2012). Optimizing radioimmunoconjugate delivery in the treatment of solid tumor. Cancer Treatment Reviews, 38(7), 854-860. [More Information]

2011

  • Huang, C., Guatelli, S., Oborn, B., Allen, B. (2011). Background Dose for Systemic Targeted Alpha Therapy. Journal of Nuclear Science and Technology, 2, 187-190.

To update your profile click here. For support on your academic profile contact .